This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Next Generation CAR & T Cell Therapies

LAST CHANCE: REGISTER BY MAY 20 TO SAVE UP TO $300

  • 00
    DAYS
  • 00
    HRS
  • 00
    MINS
  • 00
    SECS
June 14-16, 2022
Delivered as a Hybrid EventIntercontinental Mark Hopkins Hotel, San Francisco, California

Leah Sibener
Head of Therapeutic Discovery, Co-Founder at 3T Biosciences, USA

Profile

Leah is a co-founder and VP and Head of Therapeutic Discovery at 3T Biosciences. At 3T she leads the R&D operations and strategy focusing on identifying new immunotherapy targets, and engineering T cell receptor based therapeutics. Leah has co-authored work in high-impact journals such as Cell, Science, Nature Immunology, Immunity, Elife, Nature Genetics, and PNAS. She holds a Bachelor’s degree in Biophysics from Johns Hopkins University, and a PhD in Immunology from Stanford University where she developed 3T’s target discovery platform in Chris Garcia’s research group. She was named one of Forbes’ 2018 30-under-30 in Healthcare. Prior to Stanford and 3T, Leah was a part of research teams at the Johns Hopkins Institute for Cellular Engineering in Jonathan Schneck’s Lab, as well as at Genentech in Early Discovery Immunology.

Agenda Sessions

  • Modification of CART Cells to Improve Efficacy and Epitope Spreading

    9:45am